PERNIX THERAPEUTICS HOLDINGS, INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets (usd $)

In millions of USD, except per-share amounts

	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other current assets
Income tax receivable
Note receivable, net of unamortized discount of $0 and $127, respectively
Prepaid income taxes
Deferred income tax assets - current
Held for Sale - assets, net
Total current assets

Property and equipment, net
Goodwill
Intangible assets, net
Note receivable, net of unamortized discount of $0 and $319, respectively
Other
Total assets
Current liabilities:
Accounts payable
Accrued personnel expenses
Accrued allowances
Other accrued expenses
Put option and contingent consideration - Cypress acquisition
Contingent consideration - Cypress acquisition
Interest payable
Credit facilities - current
Senior secured notes - Treximet - current
Treximet Secured Notes - current, net
Held for sale - liabilities
Credit facility - current
Restricted cash payable
Other liabilities - current
Total current liabilities

Term loan
Convertible notes - long-term, net
Exchangeable notes - long-term, net
Delayed draw term loan - long-term, net
Derivative liability
Contingent consideration
Treximet Secured Notes - long-term, net
Credit facility
Deferred income tax liability - long-term
Deferred revenue
Arbitration award
Other liabilities - long-term
Debt - long term
Total liabilities
Stockholders' deficit:
Preferred stock
Common stock, $0.01 par value, 140,000,000 shares authorized, 13,957,733 and 11,841,173 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
Additional paid-in capital
Treasury stock
Accumulated other comprehensive loss
Accumulated deficit
Total Pernix stockholders' deficit
Noncontrolling interests
Total stockholders' deficitty
Total liabilities and stockholders' deficit

Comments